Demographic and clinical characteristics in cross-sectional and longitudinal cohorts. Values are mean (SD) unless otherwise indicated.
| Characteristic | Cross-Sectional | Longitudinal† Validation | |
|---|---|---|---|
| Development | Validation | ||
| Patients, no. | 5729 | 5578 | 367 |
| Age, yrs | 60.1 (13.7) | 60.3 (13.8) | 58.7 (12.5) |
| Female, % | 75.8 | 75.3 | 77.9 |
| Caucasian, % | 82.7 | 82.5 | 85.3 |
| Rheumatoid factor positive, % | 67.8 | 70 | 82 |
| Disease duration, yrs | 11.3 (10.1) | 11.1 (9.9) | 11.8 (10.0) |
| Disease activity characteristics | |||
| Tender joints 0–28 | 3.37 (5.54) | 3.38 (5.4) | 5.65 (6.10) |
| Swollen joints 0–28 | 3.89 (5.54) | 3.86 (5.53) | 5.98 (5.50) |
| ESR, mm (normal < 20) | 24.6 (22.3) | 24.6 (22.1) | 25.9 (22.6) |
| CRP, mg/dl (normal < 1.0) | 2.96 (8.5) | 2.96 (8.7) | 2.8 (7.8) |
| Pain VAS assessment, 0–100 | 32.2 (26.6) | 31.6 (25.9) | 39.4 (26.7) |
| mHAQ, 0–3 | 0.40 (0.49) | 0.39 (0.48) | 0.50 (0.52) |
| Patient global assessment, 0–100 | 29.9 (25.9) | 29.8 (25.9) | 37.9 (26.84) |
| Physician global assessment, 0–100 | 19.5 (19.0) | 19.4 (19.2) | 29.4 (20.3) |
| Duration of stiffness, h | 1.03 (2.4) | 0.94 (2.11) | 1.34 (3.11) |
| Disease activity composite measures | |||
| mDAS28 | 3.41 (1.38) | 3.40 (1.37) | 4.21 (1.41) |
| DAS28 | 3.42 (1.54) | 3.41 (1.54) | 4.19 (1.59) |
| SDAI | 15.0 (16.1) | 14.9 (16.0) | 20.5 (17.0) |
| CDAI | 12.2 (12.0) | 12.1 (12.0) | 18.4 (13.0) |
↵† Initiators of disease-modifying antirheumatic drugs. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VAS: visual analog scale; mHAQ: modified Health Assessment Questionnaire score; mDAS28: modified Disease Activity Score with 28 joint count; DAS28: Disease Activity Score with 28 joint count; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index.